{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:09:36Z","timestamp":1777558176811,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Davos Alzheimer\u2019s Collaborative"},{"DOI":"10.13039\/100030953","name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology","doi-asserted-by":"publisher","award":["Integrated Research Initiative for Living Well wit"],"award-info":[{"award-number":["Integrated Research Initiative for Living Well wit"]}],"id":[{"id":"10.13039\/100030953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Although the usefulness of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) is well-known, their use differs widely between countries. In Japan, phospho-tau181 (p-tau181) testing for determining the cause of dementia has been covered by national health insurance since 2012 and amyloid-\u03b2 (A\u03b2)\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio for evaluating eligibility for anti-A\u03b2 antibodies has been covered since 2023. However, safety concerns and burdens limit their use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Here, we report national trends in CSF biomarker testing for AD in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used open datasets from the national database covering nearly all health insurance claims in Japan from 2014 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The annual number of health insurance claims for p-tau181 testing gradually increased from 1358 (2014) to 3420 (2023); 79\u201386% of claims were from inpatient settings throughout the study period. The number of claims was highest in the 75\u201379 age group and higher in women in older age. Regional variances were identified. The number of claims for CSF A\u03b2\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio testing in its first 3 months (December 2023 to March 2024) was 729; 56% of claims were from outpatient settings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Although the number of health insurance claims for CSF p-tau181 testing has gradually increased, this number is low compared with the previously estimated annual diagnosis of AD. Tests are often performed in inpatient settings and regional inequity exists, whereas CSF A\u03b2\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio testing is slightly more often performed in outpatient settings. These data are important for understanding the current situation before the implementation of biomarker-based AD diagnosis in Japan.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823251410102","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:24:52Z","timestamp":1766424292000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in Japan"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-0634","authenticated-orcid":false,"given":"Masanori","family":"Kurihara","sequence":"first","affiliation":[{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"The University of Tokyo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"},{"name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12372"},{"key":"e_1_3_3_4_2","first-page":"101192","article-title":"A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region","volume":"50","author":"Devenney EM","year":"2024","unstructured":"Devenney EM, Anh NNQ, Tse NY, et al. A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region. Lancet Reg Health West Pac 2024; 50: 101192.","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_3_3_5_2","first-page":"101183","article-title":"Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies","volume":"50","author":"O'Callaghan C","year":"2024","unstructured":"O'Callaghan C, Michaelian JC, Aihara Y, et al. Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies. Lancet Reg Health West Pac 2024; 50: 101183.","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70536"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2018-0016"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2023.03.007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201647"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01758-3"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240185"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03622-w"},{"key":"e_1_3_3_13_2","unstructured":"US Food and Drug Administration. 510(k) Premarket Notification. Lumipulse G Ptau217\/\u00df-Amyloid 1-42 Plasma Ratio. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=k242706 (accessed 20 August 2025)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535"},{"key":"e_1_3_3_16_2","unstructured":"Minister of Health Labour and Welfare. NDB Open Data https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html (accessed August 12 2025)."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.37737\/ace.24011"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081870"},{"key":"e_1_3_3_19_2","unstructured":"The Statistics Bureau of Japan. e-Stat portal site of official statistics of Japan https:\/\/www.e-stat.go.jp\/ (accessed 25 August 2025)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70444"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-8301.2012.00415.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12596"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100219"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103911"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.155481"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.02.010"},{"key":"e_1_3_3_28_2","volume-title":"Appropriate use guideline of cerebrospinal fluid and blood-based biomarkers for dementia","author":"Ikeuchi T","year":"2025","unstructured":"Ikeuchi T, Yamada M, Tanaka T, et al. Appropriate use guideline of cerebrospinal fluid and blood-based biomarkers for dementia. 3rd edition. [in Japanese]. https:\/\/dementia-japan.org\/wp-content\/uploads\/2025\/04\/guideline_20250331.pdf (2025).","edition":"3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13974"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251410102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823251410102","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251410102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:24:53Z","timestamp":1766424293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823251410102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["10.1177\/25424823251410102"],"URL":"https:\/\/doi.org\/10.1177\/25424823251410102","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"25424823251410102"}}